|1.||Lyman, Gary H: 9 articles (06/2014 - 07/2004)|
|2.||Crawford, Jeffrey: 8 articles (10/2013 - 01/2002)|
|3.||Malin, Jennifer: 7 articles (06/2012 - 05/2007)|
|4.||Bias, Peter: 6 articles (01/2016 - 01/2013)|
|5.||Yang, Bing-Bing: 6 articles (06/2015 - 10/2007)|
|6.||Dreiling, Lyndah: 6 articles (05/2010 - 04/2007)|
|7.||Buchner, Anton: 5 articles (01/2016 - 01/2013)|
|8.||Barron, Richard: 5 articles (11/2015 - 02/2009)|
|9.||Balducci, Lodovico: 5 articles (12/2014 - 10/2003)|
|10.||Danova, Marco: 5 articles (09/2014 - 09/2007)|
07/01/2009 - "Good efficacy of pegfilgrastim for the prevention of severe neutropenia was observed at all dose levels. "
03/01/2009 - "Day 1 administration of pegfilgrastim is as effective as day 2 administration in the prevention of neutropenia in patients with gynecologic malignancies. "
04/01/2013 - "Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens."
12/01/2009 - "Is pegfilgrastim safe and effective in congenital neutropenia? "
04/01/2014 - "Two and 4 patients, respectively, had febrile neutropenia during cycle 1. Twenty percent of patients in the balugrastim group and 19% in the pegfilgrastim group had adverse events (AEs) considered to be related to study medication; 3.9% and 4.7% of patients, respectively, experienced serious AEs. "
|2.||Breast Neoplasms (Breast Cancer)
04/01/2015 - "We conducted a double-blind, placebo-controlled, randomized trial to determine the efficacy of pegfilgrastim in reducing the risk of FN in early-stage breast cancer patients. "
03/01/2009 - "This study compared the efficacy of pegfilgrastim primary prophylaxis (PPP) with CP neutropaenia management in breast cancer. "
10/01/2015 - "A phase II, open-label, dose-finding, randomized study was performed to evaluate the recommended dose of pegfilgrastim in Japanese breast cancer patients. "
11/01/2014 - "This phase 2 study demonstrated that lipegfilgrastim 6.0 mg is the optimal dose for patients with breast cancer and provides neutrophil support that is at least equivalent to the standard 6.0-mg fixed dose of pegfilgrastim. "
01/01/2016 - "In the lipegfilgrastim group, no patients had a CTx dose reduced or omitted; eight patients in the pegfilgrastim group had a CTx dose reduced or omitted during cycles 2-4. The burden of treatment associated with myelosuppressive CTx was similar in breast cancer patients treated with lipegfilgrastim or pegfilgrastim."
08/01/2014 - "Plerixafor+pegfilgrastim is a simple, safe and effective HSPC mobilization regimen in myeloma and lymphoma, in both poor and good mobilizers, and is superior to pegfilgrastim alone."
09/01/2006 - "We evaluated the efficacy of a single 6 mg dose of pegfilgrastim for mobilizing peripheral blood stem cells (PBSC) in aggressive lymphoma patients. "
08/01/2014 - "Comparison was with 22 historical controls (HC; lymphoma n=18, myeloma n=4; poor mobilizers n=4), mobilized with pegfilgrastim alone. "
02/01/2005 - "The aim of this study was to evaluate the efficacy of pegfilgrastim, in combination with salvage chemotherapy, in mobilizing CD34(+) stem cells into the peripheral blood of pretreated lymphoma patients. "
01/01/2011 - "Although studies have been conducted to evaluate the effectiveness of pegfilgrastim to prevent FN in lymphoma patients receiving myelosuppressive chemotherapy, limited data is available to identify patients who are at risk of developing FN despite primary prophylaxis with pegfilgrastim (breakthrough FN). "
03/01/2006 - "The efficacy of a single dose of pegfilgrastim in supporting severely myelosuppressive regimens in previously treated cancer patients is unknown. "
01/01/2002 - "Pegfilgrastim increases the terminal elimination half-life and decreases the apparent serum clearance of the drug in patients with nonmyeloid cancer. "
12/01/2005 - "Postregistrational trials have been conducted to evaluate the use of pegfilgrastim with emerging dose-dense regimens, in myeloid cancers and for mobilisation and engraftment of autologous stem cells. "
06/20/2014 - "We explored the efficacy and safety of neoadjuvant ddMVAC with pegfilgrastim support in muscle-invasive urothelial cancer (MIUC). "
09/01/2012 - "Women treated with adjuvant TC and pegfilgrastim at Roswell Park Cancer Institute were identified from the pharmacy database between 8/2006 and 11/2010. "
01/01/2016 - "One lipegfilgrastim recipient and two pegfilgrastim recipients were hospitalized in cycle 1 because of FN or associated infection. "
12/01/2009 - "During pegfilgrastim therapy, a severe infection occurred in two patients and recurrent ENT infections in two other patients. "
08/01/2011 - "There were more chemotherapy cycles with grade 3 and 4 infections after day 2 than day 4 pegfilgrastim (9.4% versus 6.0%; P = 0.118). "
11/01/2011 - "This study failed to demonstrate that pegfilgrastim on day 4 was more efficacious than on day 2 with respect to grade 4 leucopenia (the primary endpoint), febrile neutropenia, or infections."
06/01/2010 - "The period of critical neutropenia was relatively short in both phases and the supportive use of pegfilgrastim, although showing a trend toward reduced neutropenic period, did not appear to reduce the risk of infection in this group and may not be a critical requirement for reducing the risk of treatment-related toxicity."
|2.||Granulocyte Colony-Stimulating Factor (G-CSF)
|5.||darbepoetin alfa (Aranesp)
|1.||Drug Therapy (Chemotherapy)
|3.||Transplantation (Transplant Recipients)
|5.||Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)